ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1884

Esophageal Dilation and Interstitial Lung Disease Incidence and Progression in Systemic Sclerosis

Kimberly Showalter1, Aileen Hoffmann2, Carrie Richardson3,4, Julia (Jungwha) Lee5, David Aaby6, Rishi Agrawal7, Jane Dematte8, Rowland W. Chang9 and Monique Hinchcliff10, 1Internal Medicine, McGaw Medical Center of Northwestern University, Chicago, IL, 2Department of Medicine, Division of Rheumatology, Northwestern University Feinberg School of Medicine, Northwestern University, Chicago, IL, 3Department of Medicine, McGaw Medical Center of Northwestern University, Chicago, IL, 4Department of Rheumatology, Johns Hopkins University, Baltimore, MD, 5Preventive Medicine/Biostatistics, Northwestern University Feinberg School of Medicine, Chicago, IL, 6Northwestern University Feinberg School of Medicine, Chicago, IL, 7Radiology, Northwestern University Feinberg School of Medicine, Chicago, IL, 8Pulmonology, Northwestern University Feinberg School of Medicine, Chicago, IL, 9Institute for Public Health and Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, 10Northwestern University, Feinberg School of Medicine Scleroderma Program, Chicago, IL

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: gastrointestinal complications, interstitial lung disease, prognostic factors, pulmonary complications and systemic sclerosis

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2016

Title: Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics - Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Interstitial lung disease (ILD) is the leading cause of death in systemic sclerosis (SSc). Esophageal dysfunction and aspiration may play a role in SSc-ILD. We showed that esophageal dilation on high-resolution computed tomography (HRCT) scans correlated positively with radiographic ILD and negatively with forced vital capacity (FVC)1. We also showed that a widest esophageal diameter (WED) >=19mm on HRCT had the highest combined sensitivity and specificity for associated ILD2. The purpose of this retrospective, longitudinal study was to determine if a larger WED is a risk factor for SSc-ILD incidence and progression.

Methods: Subjects that fulfilled American College of Rheumatology 2013 SSc criteria with >= one HRCT and two pulmonary function tests were included. The first available HRCT was defined as the baseline exam. WED was measured. ILD was quantified by published methods3. In subjects without radiographic ILD and with baseline FVC >=70% predicted, incident restrictive lung disease was defined as new FVC <70% predicted. Change in FVC % predicted was used as a surrogate for ILD progression.

Results: In total, 249 subjects were included with a median follow up of 2.9 years (0.02-13.4y). Twenty-five subjects died. At baseline, 88 (82%) with a WED >=19mm had radiographic ILD compared with 94 (66%) with a WED <19mm (p=0.005; Table 1). Three of 55 without baseline ILD developed incident restrictive lung disease. At baseline, those with WED >=19mm had an 8.38 lower FVC % predicted than those with WED<19mm. In total, there was no clinically significant decline (i.e. >5% change) in FVC % predicted (Fig. 1). There was no significant difference in change in FVC % predicted between those with WED >=19 vs. <19mm (beta=0.2663; 95% CI -0.2256, 0.7583).

Conclusion: SSc-ILD often occurs before referral to a tertiary center. Those with a larger WED had an FVC % predicted at baseline that was clinically and statistically significantly lower than those with a smaller WED. Despite this, a larger WED at baseline was not associated with more rapid decline in FVC % predicted. References:   1. Richardson et al. Esophageal dilatation and interstitial lung disease in systemic sclerosis: a cross-sectional study. Semin Arthritis Rheum 2016   2. Hoffmann et al. Comment on: Esophageal dilatation and interstitial lung disease in systemic sclerosis: a cross-sectional study. Semin Arthritis Rheum 2016   3. Kazerooni et al. Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. AJR Am J Roentgenol 1997;169:977-83 Fig1.png Table1.png


Disclosure: K. Showalter, None; A. Hoffmann, None; C. Richardson, None; J. Lee, NIH, 2; D. Aaby, None; R. Agrawal, None; J. Dematte, None; R. W. Chang, NIH, 2; M. Hinchcliff, None.

To cite this abstract in AMA style:

Showalter K, Hoffmann A, Richardson C, Lee J, Aaby D, Agrawal R, Dematte J, Chang RW, Hinchcliff M. Esophageal Dilation and Interstitial Lung Disease Incidence and Progression in Systemic Sclerosis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/esophageal-dilation-and-interstitial-lung-disease-incidence-and-progression-in-systemic-sclerosis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/esophageal-dilation-and-interstitial-lung-disease-incidence-and-progression-in-systemic-sclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology